Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Investing.com - Structure Therapeutics (NASDAQ:GPCR) received a Buy rating and a $61.00 price target from Clear Street, which initiated coverage on Wednesday. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $37.50 to $120, suggesting significant upside potential from the current price of $17.83.
Clear Street views the company as "a rare opportunity in the oral drug revolution," noting that oral formulations are positioned to disrupt the diabesity market with efficacy and safety comparable to or better than current standards.
The firm highlighted Structure Therapeutics’ lead asset, aleniglipron, a small-molecule oral GLP-1 inhibitor, which could deliver proof-of-concept results with Phase 2b data expected by year-end 2025.
Clear Street also pointed to the company’s second asset, ACCG-2671, described as a first-in-class oral amylin receptor analog with transformative potential that could attract strategic partnerships.
The research firm emphasized that Structure Therapeutics appears undervalued with an enterprise value of approximately $195 million, cash reserves of $836.9 million, and a runway extending through 2027.
In other recent news, Structure Therapeutics has been the focus of several analyst reports. H.C. Wainwright reiterated its Buy rating on the company, maintaining a price target of $75.00 per share. This comes after the presentation of data from the ACHIEVE-1 trial at the American Diabetes Association Conference, highlighting the potential of oral GLP-1R agonists in diabetes treatment. Similarly, Cantor Fitzgerald maintained its Overweight rating with a $65.00 price target, citing the implications of Eli Lilly (NYSE:LLY)’s trial data for Structure Therapeutics’ aleniglipron due to structural similarities.
JMP Securities also kept its Market Outperform rating and a price target of $89.00, emphasizing the upcoming Phase 2b data for aleniglipron as a significant potential value driver. Citi analysts initiated coverage with a Buy rating and a $60.00 price target, noting the potential of aleniglipron and Structure Therapeutics’ diverse pipeline. The company’s lead drug candidate, aleniglipron, is currently in Phase 2b trials for obesity, with results anticipated by the end of 2025. Analysts from Citi suggest that aleniglipron could be a strong competitor in the obesity treatment market based on promising trial data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.